|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Swelling and drug release in hydrogel matrices: polymer viscosity and matrix porosity effects 显示文摘 | Bettni R Colombo P Massimo G | 1994 | Eur J Pharm Sci1994，2，3： | 2 |
| 2 | The Effect of Public Subsidies on Firms’Investment-cash Flowsensitivity:Transient or Persistent?显示文摘 | Massimo G Colombo Annalisa Crocea Massimiliano Guerini | 2013 | Research Policy2013，，42： | 1 |
| 3 | Technological regimes and innovation in services: The case of the Italian banking industry显示文摘 | Luigi Buzzacchi Massimo G Colombo Sergio Mariotti | 1995 | Research Policy1995，24，： | 1 |
| 4 | Founders' human capital and the growth of new echnology-based firms: a compen- tence-based view显示文摘 | Massimo G Colombo Luca Grilli | 2005 | Research Policy2005，，34： | 1 |
| 5 | How effective are technology incubators?Evidence from Italy显示文摘 | MASSIMO G COLOMBO MARCO DELMASTRO | | Research Policy0，31，7： | 1 |
| 6 | Drug diffusion front movement is important in drug release control from swellable matrix tablets显示文摘 | Colombo P Bettini R Massimo G | | 0，，08： | 1 |
| 7 | Swelling and drug release in hydrogel matrices:polymer viscosity and matrix porosity effects显示文摘 | Colombo P Massimo G | 1994 | Eur J Pharm Sci1994，2，2： | 1 |
| 8 | Empirical tests of optimal cognitive distance显示文摘 | Stefan Wuyts Massimo G Colombo Shantanu Durra and Bart Nooteboom | 2005 | Journal of Economic Behavior and Organization2005，58，2： | 1 |
| 9 | Au- thorising employees to collaborate with communities during working hours: When is it valuable for firms?显示文摘 | Massimo G Colombo A V Evila-Piva A V | 2012 | Long Range Planning2012，，27： | 1 |
| 10 | The effect of public subsidies on firms' investment-cash flow sensitivity: Transient or persis- tent? 显示文摘 | MASSIMO G COLOMBO ANNALISA CROCE MASSI- MILIANO GUERINI | 2013 | Research Policy2013，，9： | 1 |
| 11 | Swelling and drug release in hydro gel matrices: polymer viscosity and matrix porosity effects显示文摘 | Bettini R Colombo P Massimo G | 1994 | Eur J P harm Sci1994，2，3： | 1 |
| 12 | Drug diffusion front movement is important in drug release control from swellable matrix tablets显示文摘 | Colombo P Bettini R Massimo G | 1995 | J Pharm Sci1995，84，8： | 1 |
| 13 | Complementarity and cumulative and cumulative learning in the early diffusion of multiple technologies显示文摘 | Colombo Massimo G Rocco Mosconi | 1995 | Journal of industrial economics1995，43，3： | 1 |
| 14 | How Effec- tive Are Technology Incubators?显示文摘 | Massimo G Colombo Marco Delmastro | 2002 | Research policy2002，31，7： | 1 |
| 15 | Founders' human capital and the growth of new technology - based finns : A competence - based view 显示文摘 | Massimo G Colombo Luca Grilli | 2005 | Research Policy2005，，34： | 1 |
| 16 | F ounder’s human capital and the Growth of new technology-based firms:A competence-based view显示文摘 | Colombo G Massimo Luca Grilli | 2005 | Research Policy2005，，06： | 1 |
| 17 | Current status of first-line therapy,anti-angiogenic therapy and its combinations of other agents for unresectable hepatocellular carcinoma显示文摘Globally,hepatocellular carcinoma(HCC)is a frequently diagnosed malignancy with rapidly increasing incidence and mortality rates.Unfortunately,many of these patients are diagnosed in the advanced stages when locoregional treatments are not appropriate.Before 2008,no effective drug treatments existed to prolong survival,until the breakthrough multi-tyrosine kinase inhibitor(TKI)sorafenib was developed.It remained the standard treatment option for advanced HCC for 10 years,with a battery of other candidate drugs in clinical trials failing to produce similar efficacy results.In 2018,the REFLECT trial introduced another multi-TKI,lenvatinib,which has non-inferior overall survival compared with sorafenib.Thus,offering patients and their treating physicians two effective treatment options.Recently,immunotherapy-based drugs,such as atezolizumab and bevacizumab,have shown promising results in patients with unresectable HCC.This review summarizes clinical trial and real-world data studies of sorafenib and lenvatinib in patients with unresectable HCC.We offer guidance on the optimal choice between the two treatments and discuss the potential of immunotherapy-based combination;when more data become available,this will likely make the choice between sorafenib and lenvatinib somewhat obsolete. | Saleh A Alqahtani Massimo G Colombo | 2021 | World Journal of Gastrointestinal Oncology2021，13，12： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员